PP
LRMR icon

Paloma Partners’s Larimar Therapeutics LRMR Stock Holding History

Paloma Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-11,417
Closed -$163K – 2133
2019
Q2 		$163K Buy
+11,417
New +$304K ﹤0.01% 1579
2017
Q3 		– Sell
-12,117
Closed -$510K – 2290
2017
Q2 		$510K Buy
12,117
+1,284
+12% +$65.7K 0.01% 1536
2017
Q1 		$606K Buy
10,833
+1,606
+17% +$79.7K 0.01% 1509
2016
Q4 		$352K Buy
+9,227
New +$374K ﹤0.01% 1656

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Paloma Partners's LRMR Position: Q3 2019 in Review

Paloma Partners sold out of Larimar Therapeutics (LRMR) in Q3 2019, closing a stake of 11,417 shares — an estimated $163K sold.

Paloma Partners first reported a position in LRMR in Q4 2016 and held it in 4 quarters. The position peaked at $606K in Q1 2017. 51 funds tracked by Wall St. Rank hold LRMR as of Q3 2019.

  • Paloma Partners reported no remaining Larimar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Paloma Partners sold 11,417 Larimar Therapeutics shares in Q3 2019, an estimated $163K.
  • Paloma Partners first reported a position in Larimar Therapeutics in Q4 2016 and held it in 4 quarters.
  • Paloma Partners's Larimar Therapeutics position peaked at $606K in Q1 2017.
  • 51 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.